Peregrine Pharmaceuticals Company Profile (NASDAQ:PPHM)

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals logoPeregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. Bavituximab is its lead immunotherapy candidate. Bavituximab is a monoclonal antibody that targets and binds to phosphatidylserine (PS), a immunosuppressive molecule that is usually located inside the membrane of healthy cells, but then flips and becomes exposed on the outside of cells in the tumor microenvironment, causing the tumor to evade immune detection. The Company's subsidiary is Avid Bioservices, Inc. (Avid). Avid provides integrated current good manufacturing practices (cGMP) services from cell line development to commercial biomanufacturing.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PPHM
  • CUSIP:
Key Metrics:
  • Previous Close: $0.48
  • 50 Day Moving Average: $0.3226
  • 200 Day Moving Average: $0.3465
  • 52-Week Range: $0.28 - $1.12
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.35
  • P/E Growth: 0.0000
  • Market Cap: $123.04M
  • Outstanding Shares: 257,141,000
  • Beta: 1.26
Profitability:
  • Net Margins: -80.49%
  • Return on Equity: -90.82%
  • Return on Assets: -39.53%
Debt:
  • Current Ratio: 1.25%
  • Quick Ratio: 0.86%
Additional Links:
Companies Related to Peregrine Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Peregrine Pharmaceuticals (NASDAQ:PPHM) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $1.00 (108.99% upside)

Analysts' Ratings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Show:
DateFirmActionRatingPrice TargetDetails
9/13/2016Roth CapitalReiterated RatingNeutral$0.50View Rating Details
9/12/2016FBR & CoReiterated RatingOutperform$1.00View Rating Details
7/18/2016Noble FinancialReiterated RatingBuy$1.50View Rating Details
6/1/2015MLV & Co.Reiterated RatingBuy$3.50View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
12/12/2016Q217($0.03)($0.02)$587.49 million$23.40 millionViewN/AView Earnings Details
9/8/2016Q1($0.04)($0.05)$5.61 millionViewN/AView Earnings Details
7/14/2016Q416($0.03)($0.05)$18.78 millionViewListenView Earnings Details
3/9/2016Q316($0.07)($0.08)$7.96 million$6.71 millionViewListenView Earnings Details
12/10/2015Q216($0.09)($0.07)$9.52 millionViewListenView Earnings Details
9/9/2015Q116($0.08)($0.08)$9.67 millionViewN/AView Earnings Details
7/14/2015Q315($0.08)($0.07)$6.42 million$9.31 millionViewListenView Earnings Details
3/12/2015Q215($0.08)($0.08)$4.20 million$5.68 millionViewN/AView Earnings Details
12/10/2014Q115($0.07)($0.07)$5.82 million$6.30 millionViewN/AView Earnings Details
9/9/2014Q1($0.06)($0.08)$5.76 million$5.50 millionViewListenView Earnings Details
7/14/2014Q414($0.07)($0.06)$4.75 million$6.47 millionViewN/AView Earnings Details
3/7/2014Q314($0.06)($0.06)$5.09 million$3.90 millionViewN/AView Earnings Details
12/10/2013Q2($0.05)($0.05)$5.74 million$7.35 millionViewListenView Earnings Details
9/9/2013Q1 2014($0.05)($0.05)$4.75 million$4.69 millionViewN/AView Earnings Details
7/11/2013Q4 2013($0.06)($0.06)$3.57 million$4.25 millionViewN/AView Earnings Details
3/12/2013Q3 2013($0.07)($0.04)$3.90 million$7.04 millionViewN/AView Earnings Details
12/10/2012-0.08($0.09)($0.08)$4.03 million$4.03 millionViewN/AView Earnings Details
9/10/2012Q113($0.11)($0.07)$3.97 million$4.25 millionViewN/AView Earnings Details
7/16/2012($0.13)($0.10)ViewN/AView Earnings Details
3/9/2012($0.13)($0.13)ViewN/AView Earnings Details
12/12/2011($0.13)($0.16)ViewN/AView Earnings Details
9/9/2011($0.14)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Peregrine Pharmaceuticals (NASDAQ:PPHM)
Current Year EPS Consensus Estimate: $-0.1300 EPS
Next Year EPS Consensus Estimate: $-0.1100 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.05)($0.05)($0.05)
Q4 20161($0.05)($0.05)($0.05)
Q1 20172($0.05)($0.03)($0.04)
Q2 20171($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Peregrine Pharmaceuticals (NASDAQ:PPHM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Peregrine Pharmaceuticals (NASDAQ:PPHM)
DateHeadline
News IconFuture Profitability Analysis of Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) - The Oracle Examiner (NASDAQ:PPHM)
oracleexaminer.com - February 21 at 5:33 PM
News IconPeregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) Reaches Overbought Range - Aiken Advocate (NASDAQ:PPHM)
aikenadvocate.com - February 21 at 5:33 PM
News IconMost Active mover Update on Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) - Winfield Review (NASDAQ:PPHM)
winfieldreview.com - February 21 at 5:33 PM
News IconWhy Analysts put forward these two stocks: Peregrine ... - The USA Commerce (NASDAQ:PPHM)
theusacommerce.com - February 21 at 5:33 PM
News IconChecking the Overall Picture for Peregrine Pharmaceuticals, Inc. (PPHM) - StockNewsJournal (NASDAQ:PPHM)
stocknewsjournal.com - February 21 at 5:33 PM
News IconPeregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) Touching Most Active List Today - Winfield Review (NASDAQ:PPHM)
winfieldreview.com - February 18 at 8:01 AM
News IconThe Bears And Bulls Square Off On Peregrine Pharmaceuticals, Inc. (PPHM) - NY Stock News (NASDAQ:PPHM)
nystocknews.com - February 18 at 8:00 AM
News IconAnalysts believe Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) is worth $1.25 per share (NASDAQ:PPHM)
eleganthomesinla.com - February 17 at 8:10 PM
rttnews.com logoPeregrine Pharmaceuticals Inc. (PPHM) Has Surged To Over An 8-Month High (NASDAQ:PPHM)
www.rttnews.com - February 17 at 8:10 PM
News IconHC to deliver verdict tomorrow on new nursery admission norms (NASDAQ:PPHM)
ibusinesslines.com - February 15 at 4:44 AM
News IconEd Sheeran lands two big national TV spots in a row (NASDAQ:PPHM)
eleganthomesinla.com - February 15 at 4:44 AM
News IconHoloLens Spectator View makes it easier to show off AR creations (NASDAQ:PPHM)
ibusinesslines.com - February 14 at 11:42 PM
News IconPeregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) Insiders Move Reflect Future Prospects (NASDAQ:PPHM)
www.graffiotech.com - February 14 at 11:42 PM
investopedia.com logoPeregrine Cancer Test Clears Proof of Concept (PPHM) (NASDAQ:PPHM)
www.investopedia.com - February 11 at 7:22 PM
streetinsider.com logoPeregrine Pharma (PPHM) Says Recent Publication Highlights Proof-of-Concept Data for Exosome-Based Cancer Detection Platform (NASDAQ:PPHM)
www.streetinsider.com - February 10 at 9:08 PM
istreetwire.com logoEye Catching Stocks: Peregrine Pharmaceuticals, Inc. (PPHM), Transgenomic, Inc. (TBIO), Mattel, Inc. (MAT) (NASDAQ:PPHM)
istreetwire.com - February 10 at 9:08 PM
finance.yahoo.com logoCan the Rally in Peregrine Pharmaceuticals (PPHM) Shares Continue? (NASDAQ:PPHM)
finance.yahoo.com - February 10 at 9:08 PM
investopedia.com logoPeregrine Cancer Test Clears Proof of Concept (NASDAQ:PPHM)
www.investopedia.com - February 10 at 9:08 PM
streetinsider.com logoPeregrine Pharma (PPHM) Says Recent Publication Highlights Proof-of-Concept Data for Exosome-Based Cancer ... - StreetInsider.com (NASDAQ:PPHM)
www.streetinsider.com - February 10 at 2:50 AM
finance.yahoo.com logoRecent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian Cancer (NASDAQ:PPHM)
finance.yahoo.com - February 9 at 9:49 PM
finance.yahoo.com logo8:06 am Peregrine Pharma announces the publication of positive proof-of-concept data for a novel exosome-based cancer detection platform (NASDAQ:PPHM)
finance.yahoo.com - February 9 at 9:49 PM
News IconPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Daily Sentiment Score At 0.56 - Stock Observer (NASDAQ:PPHM)
www.thestockobserver.com - February 8 at 8:55 PM
News IconEquity Focus: Indicator Check on Shares of Peregrine Pharmaceuticals Inc. (PPHM) - Rives Journal (NASDAQ:PPHM)
rivesjournal.com - February 7 at 9:51 PM
News IconHot Stocks Among Investors: TRI Pointe Group, Inc. (TPH ... - Post Analyst (NASDAQ:PPHM)
postanalyst.com - February 7 at 8:49 AM
istreetwire.com logoEquities Trend Analysis: Peregrine Pharmaceuticals, Inc. (PPHM), Abercrombie & Fitch Co. (ANF), Tenet Healthcare ... - iStreetWire (NASDAQ:PPHM)
istreetwire.com - February 7 at 8:49 AM
News IconPeregrine Pharmaceuticals Inc PPHM Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:PPHM)
www.bioportfolio.com - February 7 at 12:25 AM
News IconPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) could surge as high as $1.5 - The Newburgh Press (NASDAQ:PPHM)
newburghpress.com - February 2 at 3:08 AM
News IconPrimed for Breakout or Bust? A look at Peregrine Pharmaceuticals ... - Prospect Journal (NASDAQ:PPHM)
prospectjournal.com - January 31 at 1:00 AM
realistinvestor.com logoPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) EPS Projection At $-0.015 - RealistInvestor.com (NASDAQ:PPHM)
www.realistinvestor.com - January 31 at 1:00 AM
News IconQuarterly EPS Of Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Set At $-0.015 - Stock Observer (NASDAQ:PPHM)
www.thestockobserver.com - January 30 at 8:23 AM
News IconPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Analytical Report - The Newburgh Press (NASDAQ:PPHM)
newburghpress.com - January 28 at 5:46 AM
istreetwire.com logo3 Notable Runners: MicroVision, Inc. (MVIS), Peregrine Pharmaceuticals, Inc. (PPHM), Foot Locker, Inc. (FL) - iStreetWire (NASDAQ:PPHM)
istreetwire.com - January 28 at 5:46 AM
News IconPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Bearish Target At $1.5 - Stock Observer (NASDAQ:PPHM)
www.thestockobserver.com - January 28 at 5:46 AM
News IconRSI Review on Shares of Peregrine Pharmaceuticals Inc. (PPHM) - Sherwood Daily (NASDAQ:PPHM)
sherwooddaily.com - January 26 at 1:43 AM
News IconPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Daily Sentiment Score At 0.223 - Stock Observer (NASDAQ:PPHM)
www.thestockobserver.com - January 26 at 1:43 AM
realistinvestor.com logoEPS Projection Of Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) At $-0.015 - RealistInvestor.com (NASDAQ:PPHM)
www.realistinvestor.com - January 24 at 8:30 AM
News IconGrowth Analysis of Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) - The Newburgh Press (NASDAQ:PPHM)
newburghpress.com - January 24 at 8:30 AM
finance.yahoo.com logoPeregrine Pharmaceuticals (PPHM) Sees Hammer Chart Pattern: Time to Buy? (NASDAQ:PPHM)
finance.yahoo.com - January 24 at 8:30 AM
News IconPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Bearish Target At ... - Stock Observer (NASDAQ:PPHM)
www.thestockobserver.com - January 21 at 1:10 AM
capitalcube.com logoETFs with exposure to Peregrine Pharmaceuticals, Inc. : January 20, 2017 (NASDAQ:PPHM)
www.capitalcube.com - January 20 at 8:09 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) - Wall Street Beacon (NASDAQ:PPHM)
wsbeacon.com - January 18 at 8:30 AM
News IconInvestors Swarm in on Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) - Prospect Journal (NASDAQ:PPHM)
prospectjournal.com - January 18 at 12:41 AM
bizjournals.com logoHeat Biologics to reap benefit of new biotech (NASDAQ:PPHM)
www.bizjournals.com - January 17 at 10:57 AM
istreetwire.com logoStocks Trend Analysis: TherapeuticsMD, Inc. (TXMD), Peregrine Pharmaceuticals, Inc. (PPHM), American Electric ... - iStreetWire (NASDAQ:PPHM)
istreetwire.com - January 13 at 8:01 AM
News IconAstute Investors Are Taking a Look at Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) - Prospect Journal (NASDAQ:PPHM)
prospectjournal.com - January 13 at 8:01 AM
News IconWill The Needle Move For Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:PPHM)
wsbeacon.com - January 13 at 8:01 AM
News IconJimmy Butler named Eastern Conference Player of the Week (NASDAQ:PPHM)
viveremilano.biz - January 12 at 7:55 PM
realistinvestor.com logoPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) EPS Estimate At $-0.015 - RealistInvestor.com (NASDAQ:PPHM)
www.realistinvestor.com - January 11 at 1:17 AM
News IconPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM) Quarterly EPS Set At $-0.015 - Stock Observer (NASDAQ:PPHM)
www.thestockobserver.com - January 10 at 1:00 AM
News IconPeregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) Closed the Last ... - The Newburgh Press (NASDAQ:PPHM)
newburghpress.com - January 10 at 1:00 AM

Social

What is Peregrine Pharmaceuticals' stock symbol?

Peregrine Pharmaceuticals trades on the NASDAQ under the ticker symbol "PPHM."

Where is Peregrine Pharmaceuticals' stock going? Where will Peregrine Pharmaceuticals' stock price be in 2017?

3 analysts have issued twelve-month price objectives for Peregrine Pharmaceuticals' stock. Their predictions range from $0.50 to $1.50. On average, they expect Peregrine Pharmaceuticals' share price to reach $1.00 in the next year.

When will Peregrine Pharmaceuticals announce their earnings?

Peregrine Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

Who owns Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.96%).

Who bought Peregrine Pharmaceuticals stock? Who is buying Peregrine Pharmaceuticals stock?

Peregrine Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy Peregrine Pharmaceuticals stock?

Shares of Peregrine Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Peregrine Pharmaceuticals stock cost?

One share of Peregrine Pharmaceuticals stock can currently be purchased for approximately $0.48.

Peregrine Pharmaceuticals (NASDAQ:PPHM) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Earnings History Chart

Earnings by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Dividend History Chart

Dividend Payments by Quarter for Peregrine Pharmaceuticals (NASDAQ:PPHM)

Last Updated on 2/22/2017 by MarketBeat.com Staff